RDY:NYSE
Dr Reddy's Laboratories Ltd
$12.32
arrow_upward
+0.57%(+0.070) 1D
$12.32
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 5, 4:00:03 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RDY...
Open
$12.25
High
$12.34
Low
$12.16
Mkt. cap
10.49B
Avg. vol.
2.92M
Volume
0.00
Dividend
0.68%
Quarterly dividend
$0.02
Ex-dividend date
Jul 10, 2026
P/E ratio
29.86
52-wk high
$15.67
52-wk low
$11.36
EPS
$0.41
Beta
0.30
Shares outstanding
834.64M
No. of employees
28K
Open
$12.25
High
$12.34
Low
$12.16
Mkt. cap
10.49B
Avg. vol.
2.92M
Volume
0.00
Dividend
0.68%
Quarterly dividend
$0.02
Ex-dividend date
Jul 10, 2026
P/E ratio
29.86
52-wk high
$15.67
52-wk low
$11.36
EPS
$0.41
Beta
0.30
Shares outstanding
834.64M
No. of employees
28K
News stories
From web sources and news partners
Univest
·
4 hours ago
3 Pharma Stocks With a Strong Future Roadmap: Sun Pharmaceutical Industries, Cipla and Dr. Reddy's Laboratories
AD HOC NEWS
·
7 hours ago
Dr. Reddy's reports $32,350 IRS penalty: what it means for Dr. Reddy's Laboratories stock
TradingView
·
22 hours ago
Healthcare shares extend decline for 3rd day; Sun Pharma, Dr. Reddy's fall up to 1%
TipRanks
·
23 hours ago
Dr. Reddy’s U.S. Subsidiary Hit with Modest IRS Penalty, Assessed as Non‑Material
Profile
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
About Dr Reddy's Laboratories Ltd
CEOErez Israeli
Employees27.5K
Founded1984
HeadquartersHyderabad, Andhra Pradesh, India
SectorPharmaceutical industry
Websitedrreddys.com